Clinical Trials on Stage IV Squamous Cell Carcinoma of the Head and Neck

Total 4217 results

Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Squamous Cell Carcinoma of the Head and Neck

United States
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (PembroRad)

Squamous Cell Carcinoma of the Head and Neck

France
CellSight Technologies, Inc.
Stanford University

Completed

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Squamous Cell Carcinoma of the Head and Neck

United States
Assiut University

Completed

Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN

Squamous Cell Carcinoma of the Head and Neck

Egypt
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom

Terminated

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (PEACH)

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma

United Kingdom
Pfizer

Terminated

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, China, Taiwan, France, Australia, Hungary, Korea, Republic of, Germany, Japan, Switzerland, Ireland, Israel, United Kingdom, Italy, Poland, Belgium, Canada, Greece, Portugal, Austria, Russian Federation
Sanford Health

Completed

Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma

Squamous Cell Carcinoma of the Head and Neck

United States
University of Maryland, Baltimore
National Institute of Dental and Craniofacial Research (NIDCR)

Completed

0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Washington University School of Medicine
Novartis Pharmaceuticals

Completed

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (HNSCC)

Squamous Cell Carcinoma of the Head and Neck

United States
HiberCell, Inc.
Merck Sharp & Dohme LLC

Terminated

Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

Squamous Cell Carcinoma of the Head and Neck

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Comprehensive Cancer Network; Vanderbilt-Ingram Cancer Center

Terminated

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

Squamous Cell Carcinoma of the Head and Neck

United States
Sanofi

Completed

Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial

Head and Neck Neoplasms

China
University Health Network, Toronto

Completed

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Canada
Sanofi

Completed

Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)

Head and Neck Neoplasms

Italy
Akamis Bio

Recruiting

A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT)

Squamous Cell Carcinoma of the Head and Neck

United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
Boehringer Ingelheim

Completed

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms
Ulrich Keilholz
Charite University, Berlin, Germany; AstraZeneca

Completed

Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD)

Squamous Cell Carcinoma of the Head and Neck

Germany
Debiopharm International SA

Completed

Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial

Squamous Cell Carcinoma of the Head and Neck

France, Switzerland
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Japan, Spain, Taiwan, Korea, Republic of, France, Poland, Russian Federation, Turkey
Hellenic Cooperative Oncology Group
AstraZeneca

Completed

Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. (OPHELIA)

Squamous Cell Carcinoma of the Head and Neck

Greece
International Atomic Energy Agency
Tata Memorial Centre; University of Maryland, College Park; Centro de Lucha contra... and other collaborators

Unknown

Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial (HYPNO)

Squamous Cell Carcinoma of the Head and Neck

India, Argentina, Cuba, Indonesia, Pakistan, Philippines, South Africa, Thailand, Uruguay
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)

Squamous Cell Carcinoma of the Head and Neck

China
Beth Israel Medical Center

Completed

Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck (Unilateral)

Squamous Cell Carcinoma of the Head and Neck

United States
Krzysztof Misiukiewicz
Sanofi; Icahn School of Medicine at Mount Sinai

Completed

Cabazitaxel - PF Induction Chemotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Karolinska University Hospital

Unknown

Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET)

Squamous Cell Carcinoma of the Head and Neck

Denmark, Sweden
AstraZeneca

Completed

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Squamous Cell Carcinoma of the Head and Neck

Croatia, Sweden, United States, Czech Republic, Italy, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Latvia, Lithuania, Norway, Canada, Netherlands, Argentina, Belgium, Greece, Thailand, India, Israel, Malaysia, ... and more
University of Nebraska

Terminated

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Not yet recruiting

Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome (HEAT)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

Germany
University of Erlangen-Nürnberg Medical School

Recruiting

De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck (DIREKHT2)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

Germany
Alain Algazi
Genentech, Inc.

Recruiting

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Carcinoma | Cancer | Head and Neck Cancer | Squamous Cell Carcinoma

United States
Amgen

Completed

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Cancer | Head and Neck Cancer | Oncology | Squamous Cell Carcinoma
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
Joseph Califano
Johns Hopkins University; NYU Langone Health; Greater Baltimore Medical Center; San Diego Veterans Healthcare System and other collaborators

Completed

Saliva-based Detection of CD44 (Detect 44)

Squamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Mucositis | Tongue Cancer | Oral Complications | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent... and other conditions

United States
Andrew Sikora
Advaxis, Inc.

Completed

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Fox Chase Cancer Center

Terminated

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
Kyunghee Burkitt, DO, PhD

Not yet recruiting

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC (HPV)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | HPV-Related Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage... and other conditions

United States
Danish Head and Neck Cancer Group
International Atomic Energy Agency; Danish Center for Interventional Research...

Terminated

IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck (IAEA-HypoX)

Head and Neck Carcinoma

Egypt, Estonia, Pakistan, Slovenia
Emory University
Vaccinex Inc.

Recruiting

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Cliniques universitaires Saint-Luc- Université...

Recruiting

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer (UCL-Xenog)

Squamous Cell Carcinoma of the Head and Neck

Belgium
Turku University Hospital

Completed

Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

Finland
Washington University School of Medicine

Withdrawn

Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device

Squamous Cell Carcinoma of the Head and Neck

United States
Providence Health & Services
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab for Head and Neck Cancer Patients

Squamous Cell Carcinoma of the Head and Neck

United States
Celldex Therapeutics

Completed

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Squamous Cell Carcinoma of the Head and Neck

United States
Yale University

Withdrawn

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Squamous Cell Carcinoma of the Head and Neck

Clinical Trials on Stage IV Squamous Cell Carcinoma of the Head and Neck

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations